Pharmacokinetic characterization of krca-0008 as a novel potent and selective anaplastic lymphoma kinase inhibitor for anticancer treatment

• In: Poster presentation
• At: Seoul (South Korea) (2017)
• Type: Poster
• Poster code: POS-PAA-001
• By: AHN, Sung-Hoon (Kangwon National University, College of Pharmacy, Chuncheon, Korea, Republic Of)
• Co-author(s): Sung-Hoon Ahn: College of Pharmacy, Kangwon National University, Chuncheon, Korea, Republic Of
  
• Abstract:

  Background

  KRCA-0008, bis-ortho-alkoxy-para-piperazinesubstituted-2,4-dianilinopyrimidines, has been under development as a potent and selective Anaplastic lymphoma kinase (ALK) and Ack1 dual inhibitor for anti-cancer treatment. KRCA-0008 has in vivo efficacy with a modest tumor growth inhibition in xenograft mice model bearing H3122 human lung..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login